NAGESHWARA V. DASARI to Vascular Endothelial Growth Factor Receptor-1
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Vascular Endothelial Growth Factor Receptor-1.
Connection Strength
0.206
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
Score: 0.206